title: Considerations in the design of clinical trials for cognitive aging.
abstract: What will it take to develop interventions for the treatment of age-related cognitive decline? Session V of the Summit provided perspectives on the design of clinical trials to evaluate promising but unproven interventions, and some of the steps needed to accelerate the discovery and evaluation of promising treatments. It considered strategies to further characterize the biological and cognitive changes associated with normal aging and their translation into the development of new treatments. It provided regulatory, scientific, and clinical perspectives about neurocognitive aging treatments, their potential benefits and risks, and the strategies and endpoints needed to evaluate them in the most rapid, rigorous, and clinically meaningful way. It considered lessons learned from the study of Alzheimer's disease, the promising roles of biomarkers in neurocognitive aging research, and ways to help galvanize the scientific study and treatment of neurocognitive aging.
authors.affiliation: Banner Alzheimer's Institute, Banner Research, Translational Genomics Research Institute, University of Arizona College of Medicine, and Arizona Alzheimer's Consortium, Phoenix AZ 85006, USA. eric.reiman@bannerhealth.com.
authors.forename: Eric M
authors.initials: EM
authors.lastname: Reiman
authors.forename: Roberta Diaz
authors.initials: RD
authors.lastname: Brinton
authors.forename: Russell
authors.initials: R
authors.lastname: Katz
authors.forename: Ronald C
authors.initials: RC
authors.lastname: Petersen
authors.forename: Selam
authors.initials: S
authors.lastname: Negash
authors.forename: Dan
authors.initials: D
authors.lastname: Mungas
authors.forename: Paul S
authors.initials: PS
authors.lastname: Aisen
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000375:Aging / Q000523:psychology*; D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D015415:Biomarkers; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D055808:Drug Discovery; D006801:Humans; D008928:Mitochondria / Q000502:physiology; D010085:Oxidative Phosphorylation; D012107:Research Design; D057170:Translational Research, Biomedical
chemical_list: D015415:Biomarkers; D000255:Adenosine Triphosphate